Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. - Test2 - elhamkhani - TriplyDB

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

http://www.wikidata.org/entity/Q35895214

about

Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting Role of Biomarkers in the Development of PARP Inhibitors Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Comprehensive mutation profiling of mucinous gastric carcinoma.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovaria DNA Repair Pathway Alterations in Bladder Cancer.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know The development of PARP inhibitors in ovarian cancer: from bench to bedside Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells.Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protoc PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency Genetic and molecular changes in ovarian cancer.RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.Molecular Pathways: Targeting ATR in Cancer Therapy Advances in PARP inhibitors for the treatment of breast cancer.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.Niraparib for the treatment of ovarian cancer.Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

P2860

Q23923997-FBBB82D1-BA4F-4758-A902-F3B38016350F Q26753159-62486433-34E0-4E82-A371-21EF7F3801F9 Q26780387-2F81D929-9021-4CA4-917E-C23DD81E50A0 Q26783551-3E5511A4-4453-4710-A0A9-A1859981EFF4 Q27853392-2BDDFD3C-E8B9-4233-BBCE-146316571ADF Q28071345-27D46BCA-0A44-45BA-8E30-DF6289CFE2BF Q28271944-D0A03323-E911-46D4-921F-5BDCA1C5097B Q30240245-2D4226FD-020B-4918-B450-BE39FA578AFA Q33438615-E6CD07EA-7818-451A-912F-215214B5794F Q33607945-C4EEF79F-29DB-41EF-8596-4A884A661247 Q33617922-C124BB6D-ECA5-4262-9E5D-2B6FDA7EB55F Q35816698-1B9537D3-E0A5-47EA-8EAA-468B59F3058A Q36129160-672B71E7-4246-478E-8BF6-388E08B65962 Q36259861-862222C3-3E71-4029-A89C-3C7C9581A928 Q36731185-6CF553C9-8363-4D86-9F21-8471C59FCCF6 Q36752056-F89BAF1A-D643-4740-A725-CF4B77BEA783 Q36762503-30504BDF-36AD-4ECF-B84D-AAA988621B8B Q36767034-415A2773-6B19-4697-A160-CCAEC2F0C80D Q36879506-6BD280DB-9A92-4C4F-955A-EE39C6A74AEE Q37024369-1EA7A01F-38B4-4860-817B-B5CACAF879C0 Q37057758-948A457C-3FB1-457E-9783-F1995F8F5307 Q37094076-D7236C09-C263-4B23-ABDD-68F7871B918A Q37137877-54BACA6F-7E20-4AE9-AA15-3701D2536224 Q37158437-D9BEB800-E722-46DC-B57C-CF96CA0B2595 Q37309889-A4B8EF28-8B0F-4BE6-A7E4-816ACB96654D Q37631697-A4FD3E70-477D-49E4-9768-8A8F75B02D0A Q37634102-F905CD9C-3B5D-43F3-8B68-B2EFD489E377 Q37687452-BC7493BA-ACC9-41F7-B834-CC55DC1E8EFB Q37726508-F2B4BC8B-B44D-4139-BF37-B68B177BE11D Q38393818-8963D21A-4583-463C-813F-85C32CA48BF6 Q38585436-96EBBA2E-F240-4C86-B4EA-7964505C83AC Q38612128-B6B03456-8ED1-456C-B97F-DC449117F676 Q38631373-DBAE4679-E330-48EE-95A4-4E798DD574BD Q38645200-2724A98A-21ED-4BD7-94DB-6090352AE28A Q38725254-6444362B-8F68-4735-A614-E047F0E55763 Q38744399-CC6CDB54-0C25-4EA8-8C95-5A4A501EB438 Q38747272-0A3B6AF5-D937-4924-9A1F-0DE6FACB1851 Q38756596-3DC7FFA3-229A-4381-B0B8-865C3793AEFB Q38764341-19D6775C-5BE0-4736-8929-A7FF14186F2A Q38777616-B14D781C-98F9-4600-BF8B-089588042F84

P2860

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

http://www.wikidata.org/entity/Q35895214

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@ast

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@en

type

label

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@ast

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@en

prefLabel

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@ast

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

@en

P1433

Q35895214-2F0F7283-6287-407A-8AE1-6C5E8F28DF1B

P1476

Q35895214-8128B38D-37F6-4DDD-A77E-9AAE8DB78487

P2093

Q35895214-8C8C6492-A469-4EC2-96C8-8D2597FF942C

Q35895214-C12DB4FC-D0EF-49D0-A238-62689B3410BA

P2860

Q35895214-03907D62-9C0F-4A68-B9BB-F7A3252F9CDD

Q35895214-03BF4009-FA8C-4F40-B186-D735AD1B7643

Q35895214-05C22238-412A-4EDA-8470-1EA36EC2BAC5

Q35895214-0AB6FE21-734B-404A-8286-B02561946499

Q35895214-0C61706F-69CC-4449-86A5-D81F965D7F9D

Q35895214-0CE84A12-5880-4F63-8286-3E82B4B08D6D

Q35895214-0E6211C3-76F6-4440-85B3-4DC3C3EA4D51

Q35895214-130E09CD-FA35-4F47-A56B-7D6649DDE093

Q35895214-13659E83-203A-4DA1-9D11-C81E559F5E0C

Q35895214-13CB1830-3BB2-4753-96EA-72DD09CBC19E

P304

Q35895214-552795F5-82CA-4EB7-98F1-AEAA9B74BC30

P31

Q35895214-BE9294A9-0671-4E6B-8726-C0A06387A6E7

P356

Q35895214-5254B74A-2344-460C-8E93-10DAB40D28C1

P407

Q35895214-83448D9C-E377-4685-9C74-C835B0820D27

P433

Q35895214-C4A1125E-6C52-4A40-BA1A-497DC45DC275

P478

Q35895214-1CF52584-AC43-4E74-8431-A279D16847BD

P50

Q35895214-92228332-7A41-4E18-A909-0444FBEA7EB4

P577

Q35895214-FEB077D9-072F-4B3B-B57C-44AF35DE6973

P698

Q35895214-11775343-E658-4A50-9D36-E159A134B6FC

P932

Q35895214-664FBBC9-CD25-4F46-92C5-7E2F7271DF5A

P356

JCO.2014.58.8848

P1433

Journal of Clinical Oncology

P1476

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development

@en

P2093

Clare L Scott

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Swisher

http://www.w3.org/2001/XMLSchema#string

P2860

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway

Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation

Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

PARP-3 and APLF function together to accelerate nonhomologous end-joining

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

P304

1397-1406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.58.8848

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Scott H Kaufmann

P577

2015-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25779564

http://www.w3.org/2001/XMLSchema#string

P932

4517072

http://www.w3.org/2001/XMLSchema#string